Legal 500 US 2021 Highlights Cooley
Palo Alto – July 19, 2021 – The Legal 500 United States 2021 recognized 29 Cooley practice areas and recommended Cooley as a top-tier firm for capital markets: equity offerings; healthcare: life sciences; venture capital and emerging companies; and technology transactions. Eleven lawyers were recognized as leading lawyers in their respective fields, with two lawyers, including Cooley’s chairman emeritus, being singled out for leading in trials. Eight lawyers were noted in the hall of fame, while six others were recognized as next generation partners. In total, more than 100 Cooley lawyers were recommended in The Legal 500 United States 2021 editorial.
The following Cooley practices and lawyers were highlighted:
Recommended practice groups
Denotes tier 1 ranking
Capital markets: equity offerings: advice to issuers
Capital markets: equity offerings: advice to managers
Commercial lending
Corporate investigations and white-collar criminal defense
Cyber law (including data privacy and data protection)
Employee benefits, executive compensation and retirement plans: transactional
Fintech
General commercial disputes
Healthcare: life sciences
International arbitration
Land use/zoning
Leading trial lawyers
M&A: large deals ($1bn+)
M&A: middle-market ($500m-999m)
Merger control
Patents: litigation (full coverage)
Patents: prosecution (including re-examination and post-grant proceedings)
Private equity funds (including venture capital)
Real estate
Securities litigation: defense
Technology transactions
Telecoms and broadcast: regulatory
Telecoms and broadcast: transactions
Trade secrets (litigation and non-contentious matters)
Trademarks: litigation
Trademarks: non-contentious (including prosecution, portfolio management and licensing)
Transport: aviation and air travel – litigation and regulation
US taxes: contentious
US taxes: non-contentious
Venture capital and emerging companies
Leading lawyers
Keith Berets |
Technology transactions |
Ivor Elrifi |
Healthcare: life sciences |
Koji Fukumura | Securities litigation: defense |
Colleen Gillis |
Land use/zoning |
Heidi Keefe |
Patents: litigation (full coverage) |
Charlie Kim | Capital markets: equity offerings |
Jamie Leigh | M&A: middle-market ($500m-999m) |
Mika Reiner Mayer |
Patents: prosecution (including re-examination and post-grant proceedings) |
David Peinsipp | Capital markets: equity offerings |
Rachel Proffitt |
Venture capital and emerging companies |
Michael Rhodes |
Leading trial lawyers |
Hall of fame
Barbara Borden |
M&A: middle-market ($500m-999m) |
John Crittenden |
Trademarks: litigation |
Alexander Lee |
US taxes: non-contentious |
Fred Muto |
Venture capital and emerging companies |
Stephen Neal |
Leading trial lawyers |
Michael Rhodes |
Leading trial lawyers |
Adam Ruttenberg |
Telecoms and broadcast: transactions Technology transactions |
Mark Tanoury |
Venture capital and emerging companies |
Next generation partners
Ben Beerle |
M&A: middle-market ($500m-999m) |
Kate Hillier |
Healthcare: life sciences |
Sale Kwon |
Venture capital and emerging companies |
Richard Segal |
Capital markets: equity offerings |
Adriana Wirtz |
US taxes: contentious |
Recommended lawyers
Peter Adams |
Securities litigation: defense |
DeAnna Allen |
Patents: litigation (full coverage) |
Michael Attanasio |
Trade secrets (litigation and non-contentious matters) |
Andrew Barr |
Transport: aviation and air travel - litigation and regulation |
Michael Basile |
Telecoms and broadcast: transactions Telecoms and broadcast: regulatory |
Ben Beerle |
M&A: middle-market ($500m-999m) |
Keith Berets |
Technology transactions |
Laura Berezin |
Healthcare: life sciences |
Max Bernstein |
Patents: litigation (full coverage) |
Ryan Blair |
Securities litigation: defense |
Eric Blanchard |
Capital markets: equity offerings |
Barbara Borden |
Healthcare: life sciences M&A: middle-market ($500m-999m) M&A: large deals ($1bn+) |
Matthew Brigham |
Patents: litigation (full coverage) Trade secrets (litigation and non-contentious matters) |
Nicole Brookshire |
Capital markets: equity offerings |
Matthew Brown |
Cyber law (including data privacy and data protection) |
Fraser Brown |
Patents: prosecution (including re-examination and post-grant proceedings) |
Alfred Browne |
Fintech |
David Burns |
Merger control |
Kay Chandler |
Healthcare: life sciences |
Adam Chase |
Technology transactions |
Reuben Chen |
Patents: litigation (full coverage) |
John Clendenin |
Private equity funds (including venture capital) |
Kevin Cooper |
M&A: middle-market ($500m-999m) |
Jon Cousin |
Patents: prosecution (including re-examination and post-grant proceedings) |
John Crittenden |
Trademarks: non-contentious (including prosecution, portfolio management and licensing) Trademarks: litigation |
John Dado |
Private equity funds (including venture capital) |
Jonathan Davies |
Patents: litigation (full coverage) |
Joseph Drayton |
Patents: litigation (full coverage) Trade secrets (litigation and non-contentious matters) |
Adam Dinow |
Venture capital and emerging companies |
Ivor Elrifi |
Healthcare: life sciences Patents: prosecution (including re-examination and post-grant proceedings) |
Parker Erkmann |
Transport: aviation and air travel - litigation and regulation |
Dean Farmer |
Patents: prosecution (including re-examination and post-grant proceedings) |
John Feore |
Telecoms and broadcast: regulatory |
Patrick Flanagan |
Commercial lending |
Erin Foley |
Patents: prosecution (including re-examination and post-grant proceedings) |
Joshua Friedman |
Employee benefits, executive compensation and retirement plans: transactional |
Koji Fukumura |
Securities litigation: defense Healthcare: life sciences |
Eamonn Gardner |
Patents: litigation (full coverage) |
Stephen Gardner |
US taxes: contentious |
Adam Gershenson |
Trade secrets (litigation and non-contentious matters) |
Bobby Ghajar |
Trademarks: non-contentious (including prosecution, portfolio management and licensing) |
Colleen Gillis |
Land use/zoning |
Rick Ginsberg |
Private equity funds (including venture capital) |
Andrew Goldstein |
Corporate investigations and white-collar criminal defense |
Shane Goudey |
Private equity funds (including venture capital) |
TJ Graham | Technology transactions |
Jon Graves |
Patents: litigation (full coverage) |
Jackie Grise |
Merger control |
Patrick Gunn |
General commercial disputes |
Div Gupta |
Capital markets: equity offerings |
J.G. Harrington |
Telecoms and broadcast: regulatory Telecoms and broadcast: transactions |
Kathleen Hartnett |
General commercial disputes Corporate investigations and white-collar criminal defense |
John Hemann |
Corporate investigations and white-collar criminal defense |
Kate Hillier |
Healthcare: life sciences |
Chris Holly |
Patents: prosecution (including reexamination and post-grant proceedings) |
Tanisha James |
Merger control |
Eric Jensen |
Capital markets: equity offerings |
Heidi Keefe |
Patents: litigation (full coverage) |
Charlie Kim |
Capital markets: equity offerings |
Kris Kleiner |
Cyber law (including data privacy and data protection) |
Mike Klisch |
General commercial disputes |
Ken Krisko |
Healthcare: life sciences |
Sale Kwon |
Venture capital and emerging companies |
Matthew Langer |
Patents: prosecution (including re-examination and post-grant proceedings) |
Samantha LaPine |
Real estate |
John Lavoie |
Real estate Land use/zoning |
Travis LeBlanc |
Cyber law (including data privacy and data protection) Telecoms and broadcast: transactions |
Alexander Lee |
US taxes: non-contentious |
Randall Lee |
Corporate investigations and white-collar criminal defense |
Jamie Leigh |
M&A: middle-market ($500m-999m) M&A: large deals ($1bn+) |
Michael Levinson |
Real estate |
Mike Lincoln |
Venture capital and emerging companies |
Mark Looney |
Land use/zoning |
Clint Massengill |
US taxes: contentious |
Mischi a Marca |
Commercial lending |
Mika Reiner Mayer |
Patents: prosecution (including re-examination and post-grant proceedings) |
Lesly McAnelly |
Patents: prosecution (including re-examination and post-grant proceedings) |
Robert McDowell |
Telecoms and broadcast: regulatory Telecoms and broadcast: transactions |
Lowell Mead |
Patents: litigation (full coverage) |
Erik Milch |
Patents: litigation (full coverage) |
Barbara Mirza |
Employee benefits, executive compensation and retirement plans: transactional |
Pat Mitchell |
Venture capital and emerging companies |
Howard Morse |
Merger control |
Phillip Morton |
Patents: litigation (full coverage) |
Alessandra Murata |
Employee benefits, executive compensation and retirement plans: transactional |
Fred Muto |
Venture capital and emerging companies |
David Navetta |
Cyber law (including data privacy and data protection) |
Stephen Neal |
Leading trial lawyers |
William O’Connor |
Transport: aviation and air travel - litigation and regulation |
Kathleen Pakenham |
US taxes: contentious |
Dave Peinsipp |
Capital markets: equity offerings |
Nyron Persaud |
Employee benefits, executive compensation and retirement plans: transactional |
Adam Pivovar |
Patents: litigation (full coverage) |
Christian Plaza |
Healthcare: life sciences |
Marya Postner |
Healthcare: life sciences |
Rachel Proffitt |
Venture capital and emerging companies |
Jason Rademacher |
Telecoms and broadcast: regulatory |
Michael Rhodes |
Cyber law (including data privacy and data protection) Leading trial lawyers |
Michelle Rhyu |
Healthcare: life sciences Trade secrets (litigation and non-contentious matters) |
Christina Roupas |
Real estate investment trusts Capital markets: debt offerings Capital markets: equity offerings |
Adam Ruttenberg |
Telecoms and broadcast: transactions Technology transactions |
Jason Savich |
Commercial lending |
Michelle Schulman |
Real estate |
William Schwartz |
Corporate investigations and white-collar criminal defense |
Richard Segal |
Capital markets: equity offerings |
Ian Shapiro |
General commercial disputes Trade secrets (litigation and non-contentious matters) |
Michael Sheetz |
Trade secrets (litigation and non-contentious matters) |
Lei Shen |
Cyber law (including data privacy and data protection) |
Jordan Silber |
Private equity funds (including venture capital) |
Stephen Smith |
Patents: litigation (full coverage) Trade secrets (litigation and non-contentious matters) |
Sanya Sukduang |
Healthcare: life sciences Patents: litigation (full coverage) |
Marc Suskin |
International arbitration |
Scott Talbot |
Patents: prosecution (including re-examination and post-grant proceedings) |
Mark Tanoury |
Venture capital and emerging companies |
Rachel Thorn |
International arbitration |
Michael Tollini |
Commercial lending |
Steve Tonsfeldt |
M&A: large deals ($1bn+) |
Michael Tu |
Securities litigation: defense |
Michael Tuscan |
Patents: prosecution (including re-examination and post-grant proceedings) |
Ryan Vann |
Labor-management relations |
Erich Veitenheimer |
Patents: prosecution (including re-examination and post-grant proceedings) |
Mark Weinstein |
Patents: litigation (full coverage) |
Peter Werner |
Venture capital and emerging companies |
Scott Weston |
Patents: prosecution (including re-examination and post-grant proceedings) |
Adriana Wirtz |
US taxes: contentious |
Amy Wood |
Employee benefits, executive compensation and retirement plans: transactional |
Aric Wu |
M&A litigation: defense |
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.